O

Ocean Biomedical Inc
NASDAQ:OCEA

Watchlist Manager
Ocean Biomedical Inc
NASDAQ:OCEA
Watchlist
Price: 0.0011 USD -8.33% Market Closed
Market Cap: $255.6k

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Ocean Biomedical Inc
NASDAQ:OCEA
255.6k USD
Loading...
IN
Aaswa Trading and Exports Ltd
BSE:512038
26.9T INR
Loading...
US
GE Vernova LLC
NYSE:GEV
193.6B USD
Loading...
UK
Eight Capital Partners PLC
F:ECS
158.4B EUR
Loading...
US
China Industrial Group Inc
OTC:CIND
121B USD
Loading...
US
Schlumberger NV
NYSE:SLB
72B USD
Loading...
US
Baker Hughes Co
NASDAQ:BKR
55.2B USD
Loading...
IN
GTV Engineering Ltd
BSE:539479
4.5T INR
Loading...
US
CoreWeave Inc
NASDAQ:CRWV
46.2B USD
Loading...
CH
Galderma Group AG
SIX:GALD
34.1B CHF
Loading...
US
Reddit Inc
NYSE:RDDT
34.2B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Ocean Biomedical Inc
Glance View

Market Cap
255.6k USD
Industry
N/A

Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in Providence, Rhode Island. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

OCEA Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top